Loading data for EW — first visit, this takes a few seconds.
Edwards Lifesciences Corporation
88.96 -0.32 (-0.36%)
- Capitalización de mercado
- $51.30B
- Volumen
- 308K
- Próxima fecha de resultados
- Oct 29, 2026
Edwards Lifesciences Corporation (EW): cotización, análisis y datos
Valor intrínseco
Pronóstico del analista
Previsiones bursátiles →Últimos resultados
| Reportado | Vs. estimación | Cambio interanual | |
|---|---|---|---|
| Ingresos | — | n/a | n/a |
| EPS | $0.78 | +$0.04 | +16.42% |
Métricas
- Precio de compra
- 89.07
- Ingresos (TTM)
- 6.51B
- Beneficio neto (TTM)
- 980M
- 0.85
- 1.68
- 52.98
- 26.35
- P/B (TTM)
- 4.83
- P/S (TTM)
- 7.87
- Fecha de resultados
- Oct 29, 2026
- Precio de venta
- 89.14
- Volumen
- 308,039
- Volumen medio (20D)
- 4,105,759
- Abierto
- 89.21
- Anterior Cerrar
- 89.28
- Rango del día
- 88.53 - 89.58
- Rango de 52 semanas
- 72.30 - 96.29
- analista
- n/a
- Precio objetivo
- n/a
- Dividendos
- n/a
- Fecha ex dividendo
- n/a
Acerca de Edwards Lifesciences Corporation
Ver perfil →Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Industria Medical Devices
Sector Healthcare
IPO Fecha Mar 27, 2000
Empleados 16,000
Bolsa de Valores NYSE
Símbolo bursátil EW
Sitio web https://www.edwards.com